These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8282287)

  • 21. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

  • 22. Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Feldman H; Anand R; Blesa R; Dubois B; Gray J; Homma A; Mohr E; Morris JC; Parys W; Raschig A; Robillard A
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():61-4. PubMed ID: 9305520
    [No Abstract]   [Full Text] [Related]  

  • 23. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies.
    Tomassoni D; Lanari A; Silvestrelli G; Traini E; Amenta F
    Clin Exp Hypertens; 2008 Nov; 30(8):744-66. PubMed ID: 19021025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic indications in symptomatic cognitive and psychopathological disorders in multiple sclerosis].
    Lebrun C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1085-90. PubMed ID: 11787341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group.
    Parnetti L; Senin U; Carosi M; Baasch H
    Clin Ther; 1993; 15(2):394-406. PubMed ID: 8519047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The management of coexisting depression in patients with dementia: potential of calcium channel antagonists.
    De Vry J; Fritze J; Post RM
    Clin Neuropharmacol; 1997 Feb; 20(1):22-35. PubMed ID: 9037570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Perspective of calcium antagonist].
    Kim-Mitsuyama S
    Clin Calcium; 2005 Jan; 15(1):81-6. PubMed ID: 15632476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Turning over a new leaf: Ginkgo biloba in prevention of dementia?
    DeKosky ST; Furberg CD
    Neurology; 2008 May; 70(19 Pt 2):1730-1. PubMed ID: 18458215
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of calcium channel blockers in acute ischemic cerebrovascular disease.
    Dalal PM; Dalal KP
    J Assoc Physicians India; 1995 Jun; 43(6):394-7. PubMed ID: 8906943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
    Hargreaves AC; Gunthorpe MJ; Taylor CW; Lummis SC
    Mol Pharmacol; 1996 Nov; 50(5):1284-94. PubMed ID: 8913360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dementia.
    Warner J; Butler R
    Clin Evid; 2002 Jun; (7):846-66. PubMed ID: 12230710
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
    Rozzini R; Zanetti O; Bianchetti A
    Acta Neurol (Napoli); 1993 Feb; 15(1):44-52. PubMed ID: 8456595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nimodipine in severe head injury.
    Kumar S
    Neurol India; 2004 Sep; 52(3):392-3. PubMed ID: 15472440
    [No Abstract]   [Full Text] [Related]  

  • 35. [The central effect of calcium antagonists].
    Siembab D; Janicki PK; Rewerski W
    Pol Tyg Lek; 1988 Dec 19-26; 43(51-52):1676-8. PubMed ID: 2855863
    [No Abstract]   [Full Text] [Related]  

  • 36. [Electrophysiological evaluation of the demented state and the nootropic effect of TA-0910 by "automated fluctuation analysis" of the high-frequency EEG--relation between neuropsychological test results and Lorentzian parameters].
    Nakata M
    No To Shinkei; 1996 Jun; 48(6):551-8. PubMed ID: 8703558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of nimodipine in severe diffuse head injury.
    Nandigam K
    Neurol India; 2004 Sep; 52(3):393. PubMed ID: 15472443
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists.
    Apostolakos MJ; Varon ME
    New Horiz; 1996 Feb; 4(1):45-57. PubMed ID: 8689275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes--a 12-month follow-up study.
    Selbaek G; Kirkevold Ø; Engedal K
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):528-36. PubMed ID: 18591573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I/II trial of nimodipine for HIV-related neurologic complications.
    Navia BA; Dafni U; Simpson D; Tucker T; Singer E; McArthur JC; Yiannoutsos C; Zaborski L; Lipton SA
    Neurology; 1998 Jul; 51(1):221-8. PubMed ID: 9674806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.